A Pilot- and Feasibility Trial of the EHealth Tool My COPD for People with COPD

Not Applicable

Completed

• Conditions: Chronic Obstructive Pulmonary Disease
• Interventions: Device: My COPD

• Registration Number: NCT05086341
• Lead Sponsor: Umeå University

Brief Summary

The aim of this multi-center, randomized controlled pilot- and feasibility trial is to evaluate the user satisfaction, reach and safety of My COPD, a novel eHealth tool for remote delivery of evidence-based treatment targeting people with chronic obstructive pulmonary disease (COPD). In addition, the investigators aim to collect and synthesize data on clinical outcome measures to inform the sample size estimation of a later, definitive trial.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is one of the most common non-communicable (chronic) diseases, leading to significant increased risk of morbidity and mortality. Pulmonary rehabilitation is a comprehensive intervention, including but not limited to physical exercise, education and behavioral change. Conclusive evidence supports the provision of pulmonary rehabilitation in adults with COPD, which benefits exercise tolerance, physical activity, health-related quality of life, health care use, and survival. However, access to pulmonary rehabilitation needs to be increased, which has recently been highlighted as a top priority by leading experts in the area.

To increase access to evidence-based treatment for people with COPD this research group has developed a novel eHealth tool, My COPD, in co-creation with intended end-users to meet requirements and needs of adults with COPD and health care providers. My COPD includes components to promote physical exercise, education and behavioral change, for example, information on disease management and treatment, symptom diary, an individualized physical exercise and activity plan, support from physiotherapist as well as self-management strategies. My COPD will be available on a nation-wide platform for internet-based support- and treatment programs that regional health care regions throughout Sweden offers.

The research aim of this trial is to explore the users' satisfaction, reach and safety of My COPD, and to collect and synthesize data on clinical outcome measures to inform the sample size estimation of a later definitive trial. For this purpose, the investigators will conduct a multi-center, parallel-group randomized controlled pilot- and feasibility trial, with usual care as comparison group (control), for the duration of 12 weeks. In total, 30 adults with stable COPD will be recruited from hospitals and primary care centers located in public health regions in central (Region Stockholm) and northern (Region Västerbotten) Sweden.

All participants will be invited to complete an initial screening and baseline assessment before the randomization and intervention commences. Descriptive baseline assessments that will be collected include assessment of pulmonary function (spirometry), while having usual bronchodilator therapy according to guidelines. Anthropometric data collected will include age, sex, height, weight, and body mass index. Further data that will be collected include information on smoking status, education, and co-morbidities and medications that may influence physical capacity or activity.

At completion of informed consent, enrolment and baseline assessment procedures, participants will be randomized to either the intervention group (My COPD) or control group (usual care). Randomization will be conducted using opaque envelopes, and administered by a researcher not involved in the assessment procedures, thus, ensuring concealed allocation. Participants will be randomized to the intervention (My COPD) and control group (usual care) group, using a 2:1 allocation ratio and stratified by sex and center.

Before and after the 12-week intervention assessments of exercise capacity, balance, level of physical activity, health related quality of life, COPD related symptoms, health economics will be conducted in all participants. During the intervention, data on exercise intensity, adverse events, adherence and progression will be collected from participants in the intervention group via My COPD. At intervention completion the user satisfaction of participants and health care professionals in the intervention group will be assessed. Participants in both groups will be asked to describe their COPD-related health care contacts during the study period. Physiotherapists, blinded to group allocation and previous test results, will conduct assessments.

Study Timeline

• Study First Submitted: 2021-09-26
• Study First Submitted QC: 2021-10-07
• Study First Posted: 2021-10-20
• Study Start: 2021-11-05
• Status Verified: 2023-10
• Primary Completion: 2023-10-01
• Study Completion: 2023-10-01
• Last Update Submitted: 2024-12-06
• Last Update Posted: 2024-12-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• a confirmed diagnosis of COPD

Exclusion Criteria

• inability to read and understand Swedish
• severe comorbidity that can be considered as the main contributing factor for limitation in physical activity.

In case of an exacerbation, the participant has to wait six weeks from the start of pharmacological treatment before being eligible in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
My COPD	My COPD	In addition to usual care, participants in the intervention group will receive a 12-week, twice a week, physiotherapist-supported individualized exercise program and physical activity plan via the eHealth tool My COPD.

Primary Outcome Measures

Name	Time	Method
User satisfaction	12-week follow-up (end of intervention)	The mHealth App Usability Questionnaire (MAUQ) for patients, and health care staff, with score ranging 21-147 (higher score indicating better usability)

Secondary Outcome Measures

Name	Time	Method
Health related quality of life (HrQoL)	Baseline and 12-week follow-up	The St Georges Respiratory Questionnaire (SGRQ), with score ranging from 0-100 (higher score indicating more limitation)
Health economics	During the 12-week intervention	Frequency of self-reported COPD-related health care contacts to estimate health care use (counts)
COPD related symptoms	Baseline and 12-week follow-up.	The COPD Assessment test (CAT), with score ranging 0-40 (higher score indicating more symptoms)
Level of physical activity	Baseline and 12-week follow-up	Indicator questions on physical activity (time in hours)
Physical capacity	Baseline and 12-week follow-up	The Unsupported Upper Limb Exercise test (UULEX)(time in minutes)

Trial Locations

Locations (2)

Karolinska Intitutet; 🇸🇪 Stockholm, Sweden

Umeå university; 🇸🇪 Umeå, Sweden